ALMS: Alumis Company Aggregate Debts

Alumis Inc. (ALMS) develops innovative therapies for nervous system pathologies. The company's operations rely on years of research, the results of which depend on medical trials rather than market cycles. The current metric stands at 0.04. Since commercial sales are currently absent, the company lacks the pricing power to influence product costs. This debt price chart clearly illustrates the issuer's financial structure.

Alumis Inc. - ALMS Company Debts (period 06/29/2024 - 10/27/2026)

Analytical breakdowns and data insights for company Alumis (ALMS)

- price and consensus price forecast:

Price Performance Chart Alumis Pharma|ALMS - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Alumis Corp|ALMS - Total Company Value

- book capitalization data:

Accounting Value of a Share Alumis|ALMS - Company Book Value|Market Cap to Net Assets Ratio alumis.com|ALMS - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Alumis Inc.|ALMS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Alumis Inc|ALMS - Company Debts|Debt to Book Value Ratio Alumis Corp

Analysis of all company metrics:ALMS Alumis Pharma

This metric records the total amount of obligations to external creditors, determining the issuer's financial stability. The dynamics of the total volume of borrowed funds reflect the real-time cost of capital servicing. The metric aggregates short-term and long-term loans, identifying the risk of excessive debt load. For Alumis Inc. (ALMS), this is critical when financing costly clinical trials. Debt control allows the company to maintain academic independence and attract leading scientists.

Competitor analysis for Alumis Inc.